Department of Dermatology, Venereology & Leprosy, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India.
Curr Drug Saf. 2020;15(2):160-162. doi: 10.2174/1574886315666200212093453.
Dabigatran is a novel oral anticoagulant molecule which is a direct thrombin (Factor IIa) inhibitor and is used for prevention of stroke and systemic embolism. It is easy to administer as compared to warfarin therapy as it does not require routine laboratory monitoring and has fewer drug interactions.
To present a rare case of oral ulcers secondary to dabigatran in a patient with deep vein thrombosis.
A 68-year-old female presented with painful oral ulcers, retrosternal pain and difficulty in swallowing. She had been taking capsule Dabigatran for the prevention of systemic embolism for 2 months. She had experienced symptoms of onset taking dabigatran for 7 days. Clinical examination revealed three tender, well-defined, clean looking ulcers of various sizes present over the dorsum of the tongue. Dabigatran was withdrawn and the patient was on oral proton pump inhibitors. Patient showed remarkable improvement in oral ulcers after 2 weeks.
Patient education and counseling should be done regarding this side effect of dabigatran and proper intake of this medicine.
达比加群酯是一种新型的口服抗凝药物分子，它是一种直接凝血酶（因子 IIa）抑制剂，用于预防中风和全身性栓塞。与华法林治疗相比，它更容易使用，因为它不需要常规的实验室监测，并且药物相互作用更少。
报告一例因深静脉血栓形成而继发于达比加群酯的口腔溃疡病例。
一名 68 岁女性因口腔疼痛性溃疡、胸骨后疼痛和吞咽困难而就诊。她因预防全身性栓塞而服用胶囊达比加群酯已 2 个月。她在开始服用达比加群酯 7 天后出现症状。临床检查发现舌背有三个大小不一、触痛、界限清晰、外观清洁的溃疡。停用达比加群酯后，患者开始口服质子泵抑制剂。2 周后，患者的口腔溃疡明显改善。
应就达比加群酯的这种副作用对患者进行教育和咨询，并正确服用该药。
